Print Share Email Send Email Your Name (required) ! Example: John Doe Email Address (required) ! Error: Please enter a valid sender email address. Example: firstname.lastname@example.org CC Me Recipient Email Address (required) ! Separate multiple email address with semi-colons (up to 5). Subject Subject for your email. Message (Maximum characters: 1,000) Error: Please enter your name Error: Please enter your email address Error: Please enter a valid recipient email address. Example:email@example.com Thank you! Your email has been sent to: The recipient(s) will receive an email message that includes a link to the selected article. Recipients may need to check their spam filters or confirm that the address is safe. Return to: Send Another Email An error has occurred sending your email(s). Please try again later or contact an administrator at OnlineCustomer_Service@email.mheducation.com. Return to: Twitter Facebook Linkedin Reddit Get Citation Citation AMA Citation Hong K, Lala A. Hong K, Lala A Hong, Kimberly, and Anuradha Lala. "Inorganic Nitrite Delivery to Improve Exercise Capacity in Heart Failure with Preserved Ejection Fraction: The INDIE Trial." Hurst's the Heart Updates, 24 May 2016. McGraw-Hill, New York, NY, 2016. AccessCardiology. http://accesscardiology.mhmedical.com/updatesContent.aspx?gbosid=424347§ionid=189592035 MLA Citation Hong K, Lala A. Hong K, Lala A Hong, Kimberly, and Anuradha Lala.. "Inorganic Nitrite Delivery to Improve Exercise Capacity in Heart Failure with Preserved Ejection Fraction: The INDIE Trial." Hurst's the Heart Updates Fuster V. Fuster V Fuster, Valentin. New York, NY: McGraw-Hill, 2016, http://accesscardiology.mhmedical.com/updatesContent.aspx?gbosid=424347§ionid=189592035. Download citation file: RIS (Zotero) EndNote BibTex Medlars ProCite RefWorks Reference Manager Mendeley © Copyright Tools Clip Full Chapter Figures Only Tables Only Videos Only Supplementary Content Top Inorganic Nitrite Delivery to Improve Exercise Capacity in Heart Failure with Preserved Ejection Fraction: The INDIE Trial by Kimberly Hong, MD; Anuradha Lala, MD, Listen + +Update to Chapter 70: The Diagnosis and Management of Chronic Heart Failure Study Summary + +Impaired nitric oxide (NO) signaling has been postulated to play a key role in the pathophysiology of heart failure with preserved ejection fraction (HFpEF). The INDIE-HF trial sought to assess whether 4 weeks of inhaled inorganic nitrite (which functions as an in vivo reservoir for NO generation) would improve peak oxygen consumption (pVO2) during cardiopulmonary exercise testing in patients with HFpEF. Patients who tolerated a run-in dose of inorganic nitrite (80mg) were randomized to either placebo first (N = 52; with cross-over to inorganic nitrite) or inorganic nitrite first (N = 53; with cross-over to placebo) in this double-blinded cross-over study. Baseline characteristics were similar between the two treatment groups, except more females were included in the nitrite first group (68% vs 44%; p<0.05). No difference in the primary outcome — pVO2 difference — was observed after 4 weeks of inorganic nitrite, compared to placebo (p = 0.27). Similarly, no differences were found in the secondary outcomes of change in accelerometry, quality of life, NT-proBNP or New York Heart Association (NYHA) class (see accompanying Hurst’s Central Illustration). + Targeting Altered cGMP-NO Signaling in HFpEF Graphic Jump LocationView Full Size|Favorite Figure|Download Slide (.ppt) Commentary + +Study Strengths: The pathophysiology of HFpEF is heterogeneous, thus therapies must target specific mechanistic pathways for an assessment of improvement in outcomes. While prior trials targeting the NO pathway, with such therapeutics as phosphodiesterase inhibitors and organic nitrates have been negative, INDIE-HF tested an alternative pathway for NO generation. The cross-over design minimized variability in treatment responses, and its 2 week drug-free period reduced any carryover effect from the prior inhaled nitrite phase. Additionally, by assessing tolerability of the study drug prior to randomization, drop-out rates were limited. The study utilized accelerometers to capture changes in daily activity levels, a contemporary method of assessing important patient information not otherwise captured during standard evaluations. Improvement in peak VO2 represents a valid primary endpoint as limitations in exercise tolerance remain central to the HFpEF syndrome. +Study Limitations: The study drug was administered at home, which may have increased variability in drug delivery and compliance. Additionally, adequate drug delivery was not measured and although the inhaled nitrite dose was uptitrated based on tolerability, a dose dependent response could not be assessed. +Next Steps/Clinical Perspective: The lack of efficacy of phosphodiesterase inhibitors, organic nitrates and now inorganic nitrites call into reconsideration the targeting of altered cGMP-NO signaling as a means to improve outcomes in HFpEF. Further refinement of therapies targeting the HFpEF phenotype studied may allow for relevant improvements in exercise capacity to be observed.